Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer.

Journal of surgical oncology - 1 Jan 2008

Sasa Mitsunori, Bando Yoshimi, Takahashi Masako, Hirose Toshiyuki, Nagao Taeko

Abstract excerpt

BACKGROUND: Triple-negative breast cancer (estrogen receptor-negative, progesterone receptor-negative and Her2-negative) can be classified into two subtypes: basal and non-basal phenotype. Among these subtypes the basal phenotype is associated with poor outcome. Ordinarily, clinicopathological testing involves only screening for ER, PgR and Her2, and for this reason the therapeutic approach that is decided for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to EGFR gene

Share to Immunohistochemistry

Share to Lymphatic Metastasis

Share to Phenotype

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Source

Identifiers

PMID: 17929254
DOI: 10.1002/jso.20906

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer.PMID 17929254Read ↗

How basal are triple-negative breast cancers?Semantic proximity Read ↗

Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.Semantic proximity Read ↗

Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables.Semantic proximity Read ↗

Basal breast cancer: a complex and deadly molecular subtype.Semantic proximity Read ↗

Basal cytokeratin expression in relation to immunohistochemical and clinical characterization in breast cancer patients with triple negative phenotype.Semantic proximity Read ↗

Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.Semantic proximity Read ↗

P-cadherin, vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study.Semantic proximity Read ↗

Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.Semantic proximity Read ↗

Biomarkers for Basal-like Breast CancerSemantic proximity Read ↗

Basal phenotype breast cancer: implications for treatment and prognosis.Semantic proximity Read ↗

[Basal-like breast cancer: a review].Semantic proximity Read ↗

[Basal-like breast cancers: clinicopathological features and outcome].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.